FDA Draft Guidance: Adaptive and Platform Trial Designs for Oncology

Summary

The FDA has issued draft guidance clarifying expectations for adaptive and platform trial designs in oncology drug development. Addresses biomarker-driven enrichment, dose optimization integration, master protocol statistical frameworks, and regulatory considerations for adding or removing treatment arms during conduct.